Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: diagnosed and treated reasonably according to the clinical guidelines and clinical pathways.
- Who it may be relevant to
- Registry conditions: Pituitary Adenoma, Neuroendocrine Tumors. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early postoperative period, which is invasive and has a poor prognosis. Therefore, it is important to find imaging, histological or serum molecular markers for early prediction of the invasiveness and clinical prognosis of pituitary neuroendocrine tumors. The aim of this study is to observe the changes of biomarkers and imaging features in serum or tissues of pituitary neuroendocrine tumors during the course of disease and treatment, and to explore the biomarkers and imaging features that can predict the proliferation, progression and recurrence risk of pituitary neuroendocrine tumors after medical or surgical treatment.
Interventions
- Other diagnosed and treated reasonably according to the clinical guidelines and clinical pathways
The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
Primary outcome measures
- Disease progression or recurrence after surgery [Time frame: up to 5 years]
Eligibility criteria
Inclusion criteria
Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.
Exclusion criteria
- Previous pathological specimen suggested pituitary carcinoma.
- always have received radiation and chemotherapy or immune and targeted therapy of the patients.
- with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients.
- there are ectopic neuroendocrine tumor patients.
- within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery.
- crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis).
- peripheral glands or other solid tumors in patients with severe disease or blood system.
- serious organ damage such as heart, kidney, liver, etc.
- with severe mental or nervous system disease.
- serious high blood glucose or poorly controlled hypertension or emergency patients.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- endocrinology department of the first affiliated hospital of Sun Yat-sen University — Guangzhou
Identifiers
NCT: NCT06015802 · 2021450